CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

RDVWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2164 Placebo to Match RDV Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting

The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in reducing the rate of hospitalization or death in non-hospitalized participants with early stage coronavirus disease 2019 (COVID-19) and to evaluate the safety of RDV administered in an outpatient setting.

NCT04501952 COVID-19 Drug: RDV Drug: Placebo to Match RDV

Primary Outcomes

Measure: Composite Endpoint Measuring Proportion of Participants Hospitalized or Death From Any Cause by Day 14.

Time: From date of randomization up to Day 14

Measure: Proportion of Participants Experiencing Treatment-Emergent Adverse Events

Time: From date of randomization up to 3 days plus 30 days

Secondary Outcomes

Measure: All-cause Mortality at Day 28

Time: Day 28

Measure: Rate of Hospitalization by Day 28

Time: Day 28

Measure: Time-weighted Average Change in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load from Baseline to Day 7

Time: Baseline; Day 7

Measure: Time to Resolution of COVID-19-Related Symptoms

Time: First Dose Date Up to Day 28

No related HPO nodes (Using clinical trials)